You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

copanlisib

Showing 1 - 25 of 26
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Rituximab, Copanlisib)

Recruiting
  • Follicular Lymphoma
  • +2 more
  • Rituximab
  • Copanlisib
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 18, 2022

Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
May 13, 2022

Non Small Cell Lung Cancer Trial in Lexington (Durvalumab, Copanlisib)

Recruiting
  • Non Small Cell Lung Cancer
  • Lexington, Kentucky
    Markey Cancer Center
Feb 21, 2022

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
May 4, 2022

Leukemia, Acute Lymphocytic Trial in Durham (Copanlisib)

Recruiting
  • Leukemia, Acute Lymphocytic
  • Copanlisib
  • Durham, North Carolina
    Duke Cancer Center
Jun 28, 2022

Mature T-Cell and NK-Cell Tumor Trial in Hwasun-gun (Copanlisib, Gemcitabine)

Completed
  • Mature T-Cell and NK-Cell Neoplasm
  • Hwasun-gun, Jeollanam-do, Korea, Republic of
    Chonnam National University Hwasun Hospital
Jun 9, 2022

Locally Advanced Malignant Solid Tumor, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Solid Tumor Trial

Withdrawn
  • Locally Advanced Malignant Solid Neoplasm
  • +3 more
  • (no location specified)
May 24, 2022

Endometrial Cancer, Ovarian Cancer Trial in Houston (Copanlisib, fulvestrant)

Not yet recruiting
  • Endometrial Cancer
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Los Angeles (procedure, drug, other)

Terminated
  • Estrogen Receptor Positive
  • +16 more
  • Biopsy of Breast
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Apr 4, 2022

Non-Hodgkin Lymphoma Trial in Switzerland (Copanlisib, Venetoclax)

Terminated
  • Non-Hodgkin Lymphoma
  • Basel, Switzerland
  • +5 more
Mar 18, 2022

Follicular Lymphoma, Endometrial Cancer Trial in New York (Copanlisib, Ketogenic Diet)

Recruiting
  • Follicular Lymphoma
  • Endometrial Cancer
  • Copanlisib
  • Ketogenic Diet
  • New York, New York
  • +2 more
Nov 24, 2021

Biliary Carcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Trial in Tampa (Cisplatin, Gemcitabine, Copanlisib)

Completed
Has Results
  • Biliary Carcinoma
  • +3 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Aug 3, 2021

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Recruiting
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 15, 2022

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

NSCLC (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC) Trial in Canada, United States

Active, not recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • +2 more
  • Beverly Hills, California
  • +5 more
Mar 28, 2022

Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Copanlisib
  • Nivolumab
  • Duarte, California
  • +2 more
Mar 9, 2022

Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular Trial in United States (I-124 PET/CT lesion dosimetry,

Recruiting
  • Thyroid Carcinoma
  • +5 more
  • I-124 PET/CT lesion dosimetry
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Mar 3, 2022

HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer Trial in Ireland, Spain (Copanlisib,

Terminated
  • HER2-positive Breast Cancer
  • +3 more
  • Copanlisib
  • Trastuzumab emtansine
  • Cork, Ireland
  • +3 more
Dec 14, 2020

Carcinoma, Squamous Cell of Head and Neck Trial in France (Copanlisib, Cetuximab)

Terminated
  • Carcinoma, Squamous Cell of Head and Neck
  • Angers, France
  • +6 more
Mar 24, 2021

Lymphoma, T-Cell Trial (Copanlisib, Romidepsin)

Withdrawn
  • Lymphoma, T-Cell
  • (no location specified)
Aug 11, 2020

Marginal Zone Lymphoma Trial in Austria, Germany (Copanlisib, Rituximab)

Recruiting
  • Marginal Zone Lymphoma
  • Wien, Austria
  • +19 more
Mar 14, 2022

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Copanlisib
  • +2 more
  • Los Angeles, California
  • +4 more
Jul 19, 2022

Follicular Lymphoma Trial in Germany (Copanlisib, Obinutuzumab)

Recruiting
  • Follicular Lymphoma
  • München, Bavaria, Germany
  • +39 more
May 19, 2022

Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma Trial in

Completed
Has Results
  • Endometrial Endometrioid Adenocarcinoma
  • +5 more
  • Copanlisib
  • Laboratory Biomarker Analysis
  • New Haven, Connecticut
  • +42 more
Jan 25, 2022

Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive Trial (Copanlisib, Fulvestrant, Laboratory

Withdrawn
  • Estrogen Receptor Positive
  • +3 more
  • Copanlisib
  • +3 more
  • (no location specified)
Aug 13, 2018